Trilaciclib revolutionizes the landscape of oncology therapeutics by protecting and preserving patients' bone marrow during chemotherapy. Trilaciclib's unique mechanism reduces the risk of chemotherapy-induced myelosuppression, enabling patients to undergo more effective and intensive treatment regimens. By ensuring a safer and more productive treatment journey, Trilaciclib optimizes patient outcomes and strengthens your company's commitment to advancing cancer care. Embrace this game-changer and pave the way for a new era in cancer therapeutics.

Reference

- CN114014864A

- US20140274896A1

- WO2018005865